NEW YORK, March 13, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), GW Pharmaceuticals plc (NASDAQ: GWPH), Galena Biopharma, Inc. (NASDAQ: GALE), and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Actavis plc Analyst Notes
On February 28, 2014, Actavis plc (Actavis) announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking the approval to market Colchicine Tablets USP, 0.6 mg. It is the Company's generic version of Takeda's Colcrys®, which is a prescription medicine used in adults to prevent and treat gout flares. The full analyst notes on Actavis plc are available to download free of charge at:
http://www.AnalystsReview.com/03132014/ACT/report.pdf
--
Intercept Pharmaceuticals, Inc. Analyst Notes
On March 10, 2014, Intercept Pharmaceuticals, Inc. (Intercept) announced the schedule of its earnings release and conference call on its full-year 2013 financial results. The Company will report the results on March 14, 2014, Friday. Intercept management will also conduct a conference call and audio webcast on March 17, 2014, Monday, at 8:30 a.m. EDT, to discuss the results and provide an update on the Company's business. The full analyst notes on Intercept Pharmaceuticals, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03132014/ICPT/report.pdf
--
GW Pharmaceuticals plc Analyst Notes
On February 28, 2014, GW Pharmaceuticals plc (GW) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Epidiolex®. According to the Company, it is a product candidate for the treatment of Lennox-Gastaut syndrome (LGS) in children. LGS is a rare and severe form of childhood-onset epilepsy. GW informed that FDA had granted orphan drug designation for Epidiolex in the treatment of Dravet syndrome, in November 2013. GW intends to advance a full clinical development program for Epidiolex for the treatment of both LGS and Dravet syndrome. GW is working with leading pediatric epilepsy specialists in the United States, and expects to commence an initial Phase 2 clinical trial for Epidiolex in H2 2014. The full analyst notes on GW Pharmaceuticals plc are available to download free of charge at:
http://www.AnalystsReview.com/03132014/GWPH/report.pdf
--
Galena Biopharma, Inc. Analyst Notes
On March 3, 2014, Galena Biopharma, Inc. (Galena) announced the launch of Galena Patient Services (GPS). It is a full-service support program designed to help manage patient access and reimbursement for patients taking Abstral® (fentanyl) Sublingual Tablets. "Patients suffering from breakthrough cancer pain are confronted with extraordinary issues on a daily basis, including insurance reimbursement and access," said Mark J. Ahn, Ph.D., President and CEO. "Galena Patient Services will offer support to these patients and their healthcare providers by managing the benefits approval process to make prescribing and receiving Abstral as simple as possible." Galena informed that a dedicated GPS team consults with the healthcare professionals, patients, and insurance providers to guide the benefits approval process and make prescribing and receiving Galena commercial products more simple. The full analyst notes on Galena Biopharma, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03132014/GALE/report.pdf
--
Conatus Pharmaceuticals Inc. Analyst Notes
On March 3, 2014, Conatus Pharmaceuticals Inc. (Conatus) announced the initiation of a Phase 2 clinical trial of its lead drug candidate, emricasan. Conatus further reported that the said drug candidate is for patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with inflammatory and/or fibrotic nonalcoholic steatohepatitis (NASH). The primary endpoint of this double-blind, placebo-controlled trial is a reduction of elevated levels of key biomarkers implicated in patients with NAFLD/NASH. The trial will also evaluate the safety and tolerability of emricasan in the target patient population, with top-line results expected in H2 2014. The full analyst notes on Conatus Pharmaceuticals Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03132014/CNAT/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
